Welcome to our dedicated page for Mereo BioPharma Group plc SEC filings (Ticker: MREO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Mereo BioPharma Group plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Mereo BioPharma Group plc's regulatory disclosures and financial reporting.
Mereo BioPharma Group plc reported a six‑month 2026 net loss of $13.7 million, an improvement from $27.5 million a year earlier, with no product revenue and operating expenses focused on rare‑disease programs setrusumab and alvelestat. Cash and cash equivalents were $30.1 million at June 30, 2026, versus $56.1 million at June 30, 2025, supporting management’s expectation that current resources will fund operations into late 2027.
Research and development spending fell to $6.6 million for the first half from $9.3 million, and general and administrative expenses declined to $9.2 million from $12.8 million, reflecting delayed and reduced pre‑commercial and development activities. Foreign currency movements contributed a $1.3 million gain versus an $8.1 million loss in the prior‑year period.
As a subsequent event, Mereo entered an option and license agreement with Sentynl Therapeutics granting U.S. commercial and global manufacturing rights to alvelestat. On option exercise, Mereo would be eligible for $40 million in upfront and R&D payments, up to $435 million in milestones, and double‑digit tiered U.S. royalties, while leading the global Phase 3 study.
Mereo BioPharma Group plc reported second-quarter 2026 results, highlighting a smaller net loss and an extended cash runway alongside key partnering progress. Net loss for the quarter was $7.0 million, improving from $14.6 million a year earlier, driven mainly by sharply lower research and development spending.
As of June 30, 2026, cash and cash equivalents were $30.1 million, which the company expects will fund operations into late 2027. Mereo entered an option and license agreement with Sentynl Therapeutics for alvelestat, with eligibility for $40 million in upfront and R&D payments on option exercise, up to $435 million in milestones, and double-digit tiered U.S. royalties. For setrusumab, two Phase 3 studies in osteogenesis imperfecta did not meet primary fracture endpoints but showed statistically significant gains in bone mineral density and other measures, and Mereo and Ultragenyx are in regulatory discussions on a potential path forward.
Mereo BioPharma Group plc entered into an Option and License Agreement with Sentynl Therapeutics for the U.S. commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). The agreement grants Sentynl an exclusive option to license U.S. commercialization rights while Mereo retains commercial rights for the rest of the world.
Under the terms, Mereo will receive a non-refundable option fee and, upon option exercise, would be eligible for $40 million in upfront and R&D payments, up to $435 million in potential regulatory and commercial milestones, and double-digit tiered royalties on U.S. net sales. Sentynl would also fund the alvelestat Phase 3 development program on option exercise. Mereo will lead the global Phase 3 study and regulatory interactions until completion, while the companies collaborate during a short option period to refine the Phase 3 design and advance manufacturing.
Mereo BioPharma Group plc ownership disclosure: EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman jointly report beneficial ownership on an amendment to Schedule 13G/A. The filing shows EcoR1 and Mr. Nodelman each report shared voting and dispositive power over 66,844,275 Ordinary Shares (representing 8.4% of the class). The Qualified Fund reports shared voting and dispositive power over 62,644,610 Ordinary Shares (representing 7.8%).
The filing states these Ordinary Shares are held through 13,368,855 American Depositary Shares (each ADS = 5 Ordinary Shares) and that the percentage calculations use 798,078,829 Ordinary Shares outstanding as of March 18, 2026 as reported in the issuer's Form 10-K for the fiscal year ended December 31, 2025. The reporting persons disclaim group membership and assert the holdings were not acquired to change control.
Mereo BioPharma Group plc ownership filing shows Bank of America Corporation reports beneficial ownership of 40,976,460 ordinary shares, representing 5.1% of the class. The calculation cites 798,078,829 shares outstanding as of March 18, 2026 from the issuer's Form 10-K. The filing states that the reported holdings reflect shared voting and dispositive power across Bank of America and certain wholly owned subsidiaries.
Mereo BioPharma Group plc reported the results of its 2026 Annual General Meeting, where all resolutions passed. Shareholder turnout was high, with 436,766,255 ordinary shares represented in person or by proxy.
Shareholders adopted the annual report and accounts for the year ended December 31, 2025, with 98.29% of votes cast in favor, and re-appointed PricewaterhouseCoopers LLP as auditors with 98.59% support. The Audit and Risk Committee was authorized to determine PwC’s remuneration.
Investors approved the directors’ remuneration report with 93.35% support and the directors’ remuneration policy, effective after the AGM, with 91.74% support. The compensation of named executive officers received 91.71% advisory approval. Justin Roberts, Dr. Daniel Shames and Marc Yoskowitz were each re-elected as directors, receiving around 94% of votes cast.
Shareholders also authorized the directors to allot shares and grant rights to subscribe or convert up to a maximum nominal amount of £3,591,354.73, and to do so on a non-pre-emptive basis, both authorities running until June 30, 2029. These replace earlier share issuance authorities to the extent not already used.
Mereo BioPharma Group plc filed an amended report to correct a technical item tag and reiterated its first quarter 2026 results and clinical updates. The company reported a net loss of $6.7 million for the quarter, improving from $12.9 million a year earlier, as operating loss narrowed and foreign currency gains increased.
Research and development expenses rose to $4.7 million, mainly from higher setrusumab costs, while general and administrative expenses fell to $4.0 million driven by ADR reimbursement and lower pre-commercial spending. Cash and cash equivalents were $36.2 million as of March 31, 2026, which the company expects to fund operations into mid-2027.
Clinically, neither of the two global Phase 3 studies of setrusumab in osteogenesis imperfecta met their primary fracture-rate endpoints, though both achieved strong results on key secondary measures such as bone mineral density and vertebral fractures. Mereo and partner Ultragenyx have started discussions with regulators on a potential pediatric path. Mereo is also preparing alvelestat for a single Phase 3 trial in AATD lung disease and expects its partner āshibio to start a Phase 2 vantictumab trial in ADO2 in the second half of 2026.
Mereo BioPharma Group plc reported first quarter 2026 results and updates on its rare disease pipeline. For the quarter ended March 31, 2026, net loss narrowed to $6.7 million from $12.9 million a year earlier, helped by lower general and administrative expenses of $4.0 million versus $7.3 million. Research and development spending rose to $4.7 million from $3.9 million, mainly from higher setrusumab costs.
Cash and cash equivalents were $36.2 million as of March 31, 2026, compared with $41.0 million at December 31, 2025, and the company reiterates that this is expected to fund operations into mid-2027. Setrusumab’s two Phase 3 studies in osteogenesis imperfecta did not reach their primary fracture endpoints but showed strong improvements in bone mineral density, vertebral fractures and patient-reported outcomes, with a safety profile consistent with prior studies. Mereo and partner Ultragenyx have begun discussions with regulators on a potential pediatric path.
Mereo is seeking a partner to run a single Phase 3 alvelestat trial in approximately 220 AATD-LD patients over 18 months and expects vantictumab partner āshibio to start a Phase 2 trial in ADO2 in the second half of 2026.